HCA
TRVI icon

Harbour Capital Advisors’s Trevi Therapeutics TRVI Stock Holding History

Harbour Capital Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$717K Sell
40,200
-500
-1% -$7.27K 0.13% 152
2026
Q1 		$602K Buy
40,700
+13,200
+48% +$148K 0.11% 161
2025
Q4 		$327K Hold
27,500
– – 0.07% 217
2025
Q3 		$263K Buy
+27,500
New +$206K 0.05% 250

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Harbour Capital Advisors's TRVI Position: Q2 2026 in Review

Harbour Capital Advisors reduced its Trevi Therapeutics (TRVI) stake by 1.2% in Q2 2026, selling an estimated $7.27K and leaving 40,200 shares worth $717K. The position accounts for 0.13% of the portfolio, ranked #152.

Harbour Capital Advisors first reported a position in TRVI in Q3 2025 and has held it in 4 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Harbour Capital Advisors held 40,200 shares of Trevi Therapeutics worth $717K as of Q2 2026.
  • Harbour Capital Advisors sold 500 Trevi Therapeutics shares in Q2 2026, an estimated $7.27K.
  • Trevi Therapeutics made up 0.13% of Harbour Capital Advisors's portfolio in Q2 2026, its #152 holding.
  • Harbour Capital Advisors first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Harbour Capital Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.